Novartis Talking About Fingolimod Safety With FDA; Will Talk To Advisory Panel In June
This article was originally published in The Pink Sheet Daily
Executive Summary
Structure of the REMS for oral multiple sclerosis drug Gilenia likely to be discussed at committee meeting close to review deadline.